GlassScriptPhysician profile
Afsaneh Nourin
NPI 1144288762
$1,005.61
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $172 · 2021: $21.91 · 2022: $15.08 · 2023: $138 · 2024: $375 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.53 | 2020-2024 | Tezspire, Farxiga |
| Boston Scientific Corporation | $209.02 | 2023-2024 | Watchman Access System, Watchman Flx |
| Janssen Pharmaceuticals, INC | $135.14 | 2019-2024 | Xarelto |
| Abbvie INC. | $52.83 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $52.37 | 2025 | Vowst |
| Novartis Pharmaceuticals Corporation | $40.69 | 2019 | |
| Genzyme Corporation | $35.05 | 2025 | |
| Allergan, INC. | $29.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2025 | Ofev |
| Grifols USA, LLC | $18.15 | 2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $14.28 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $14.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afsaneh Nourin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.